Treatment of clozapine induced late onset neutropenia with G-CSF and beta-glucan: Case
report Gursoy NU¹, Yildiz M¹, Ozer S¹, Yagcioglu EA¹, Haznedaroglu IC ²¹ Department of …

This case outlines recurrent neutropenia after fourteen years of successful clozapine use.
The patient has a diagnosis of treatment‐resistant schizophrenia which has been …

DISCUSSION Our case report shows that the use of G-CSF may be a valid alternative to
clozapine withdrawal in cases of very severe treatment-resistant schizophrenia and good …

The use of clozapine is limited by the potential for haematological adverse effects
(Reference Young, Bowers and Mazure Young et al, 1998). Facing the occurrence of …

BackgroundA 17-year-old boy suffering from a severe schizophrenic disorder of the
paranoid type and mental retardation did not respond to treatment with typical …

TO THE EDITOR: Prescribing guidelines for clozapine have recently changed (1). Clozapine
may now be continued if the risk of psychiatric illness outweighs the risk of recurrent severe …

The recent case report by Thompson and colleagues on late-onset neutropenia with
clozapine raises a few questions (1). The authors do not define mild neutropenia and …

Background: Treatment resistant schizophrenia (TRS) affects 20-23% of schizophrenic
patients. A recommended medication for treating TRS is clozapine which works on many …

Clozapine is considered first‐line treatment for patients with treatment‐resistant
schizophrenia, but the occurrence of neutropenia and agranulocytosis in 1% to 2% of …

Clozapine remains the most effective agent for diminishing or eliminating psychotic
symptoms in treatment-resistant patients. However, among such patients, a small …